The WACC of Xbrane Biopharma AB (XBRANE.ST) is 5.5%.
| Range | Selected | |
| Cost of equity | 5.00% - 8.60% | 6.80% |
| Tax rate | 20.60% - 20.90% | 20.75% |
| Cost of debt | 5.00% - 5.00% | 5.00% |
| WACC | 4.5% - 6.4% | 5.5% |
| Category | Low | High |
| Long-term bond rate | 2.5% | 3.0% |
| Equity market risk premium | 5.1% | 6.1% |
| Adjusted beta | 0.29 | 0.67 |
| Additional risk adjustments | 1.0% | 1.5% |
| Cost of equity | 5.00% | 8.60% |
| Tax rate | 20.60% | 20.90% |
| Debt/Equity ratio | 0.87 | 0.87 |
| Cost of debt | 5.00% | 5.00% |
| After-tax WACC | 4.5% | 6.4% |
| Selected WACC | 5.5% | |